Rebiotix
55 articles about Rebiotix
-
Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, RBX2660, at ACG 2021
10/25/2021
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced the results of two key retrospective analyses at the American College of Gastroenterology 2021 annual congress.
-
Ferring Pharmaceuticals today announced positive results across all five of its prospective trials for a live biotherapeutic designed to reduce recurrent C. difficile infection (rCDI).
-
Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties
9/29/2021
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, announced final results of an analysis from five prospective trials of its investigational microbiota-based live biotherapeutic, RBX2660, for the reduction of recurrent C. difficile infection.
-
Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021
9/22/2021
Ferring Pharmaceuticals and Rebiotix today announced they will present data from the clinical development program for RBX2660, an investigational microbiota-based live biotherapeutic for reduction of recurrent Clostridioides difficile (C. difficile) infection, as part of IDWeek 2021.
-
Ferring and Rebiotix Present Positive Interim Phase 3 Results From Open-Label Study of Investigational Microbiota-Based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)
5/22/2021
Interim analysis of the Phase 3 PUNCH™ CD3-Open-Label Study (OLS) showed positive efficacy and consistent safety with RBX2660 for up to six months in patients with recurrent Clostridioides difficile (C. difficile) infection, adding to robust evidence of largest clinical development program in microbiome-based therapeutics
-
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
5/21/2021
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
-
Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW) 2021
5/13/2021
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, announced that Phase 3 data evaluating its investigational microbiota-based live biotherapeutic RBX2660 for reduction of recurrent Clostridioides difficile infection will be presented as part of an invited talk at Digestive Disease Week® 2021.
-
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
2/17/2021
The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this patient community and help more people build families
-
Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020
10/21/2020
Ferring and Rebiotix, a Ferring Company, will present two oral abstracts describing translational studies of investigational microbiome-based therapeutics RBX2660 and RBX7455 for the treatment of recurrent Clostridioides difficile (C. diff) infection These data presentations strengthen the company’s leadership and scientific and clinical understanding of the two investigational therapeutics
-
The therapy is being developed to decrease C. difficile (C. diff) infection recurrences.
-
BioSpace Movers & Shakers, Aug. 23
8/23/2019
Biopharma companies strengthen their senior leadership teams and boards of directors with this week's appointments. -
Rebiotix, Inc and Karolinska Institutet Expand Partnership to Shape the Future of Microbiome Research
8/21/2019
Rebiotix Inc, a Ferring Pharmaceuticals company, announced today that their Chief Scientific Officer, Dr. Ken Blount, has been appointed to Karolinska Institutet’s Joint Steering Committee (JSC) of the Centre for Translation Microbiome Research (CTMR) in Stockholm, Sweden.
-
Rebiotix Leaders to Discuss Microbiome Product Development Challenges and Regulation at Microbiome Movement – Drug Development Summit 2019
6/26/2019
The fourth annual summit will take place on June 26-28 in Boston, MA.
-
Microbiota Restoration Takes the Podium at DDW 2019: Investigational Microbiota-Based Therapies for Recurrent C. diff Highlighted
5/17/2019
Rebiotix Inc, a Ferring company, will present data highlighting clinical trials of RBX2660 and RBX7455, two formulations of investigational microbiome restoration therapeutics being studied for the prevention of recurrent Clostridioides (Clostridium) difficile (C. diff) infection, at the 2019 Digestive Disease Week© (DDW) meeting, taking place May 18-21 in San Diego, California.
-
Microbiome Health Index™ Platform to be Presented at Gut Microbiota for Health Summit 2019
3/20/2019
Rebiotix’s prototype index is under development to measure impact of microbiota-based therapeutics on Clostridium difficile infection patient microbiomes
-
Rebiotix, C. Diff Foundation Commend State of Minnesota for Declaring November Clostridium difficile Awareness Month
11/1/2018
Proclamation heightens public awareness and impact of the devastating infection.
-
Rebiotix and Microbiome Insights Collaborate on a Microbiome IBD Tool for Clinical Development
10/18/2018
With a growing body of science linking gut microbiota to inflammatory bowel disease (IBD), a need exists in clinical settings to understand changes in the gut microbial community as they relate to IBD and its management.
-
Rebiotix Clinical, Microbiome Data From First-In-Class Microbiota Restoration Therapy to Be Presented at IDWeek 2018
10/1/2018
New data continues to underscore company leadership in microbiome field.
-
Arc Bio launched its proprietary antimicrobial resistance (AMR) software. It is the first in what it expects to be a series of next-generation sequencing (NGS)-based products for pathogen detection.
-
FDA’s Approval of T2 Biosystems T2Bacteria Panel Underlines Importance of Sepsis Diagnosis and Tr...
7/10/2018
On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area.